ARTICLES

Filter  
Active filters 0
Remove
  

Refine your searches by:

Collections
Biology
Medicine / Pharmacology
Medicine / Sub specialtie
Research
Chemistry
Pure sciences
Public health
Agronomy and forestry
Technology
Food and nutrition
all records (69)

Languages
English
Spanish
German
French
Portuguese

Countries
Indonesia
USA
India
Ukraine
Italy
Brazil
Romania
Iran
Canada
Bangladesh
all records (68)

Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
all records (24)

Filter  
 
6.010  Articles
1 of 601 pages  |  10  records  |  more records»
Objective: To investigate the effects of EGFR-TKI combined chemotherapy on immune function, tumor markers and oxidative stress in patients with stage-IV lung adenocarcinoma.Methods: This retrospective observational study included 116 patients with stage-I... see more

Pediatric chronic myeloid leukemia (CML) is a hematopoietic malignancy, treated by tyrosine kinase inhibitor (TKI). Previously, imatinib resistance in CML was treated with nilotinib as a second line. However, in Indonesia, where the options of TKIs are li... see more

Pediatric chronic myeloid leukemia (CML) is a hematopoietic malignancy, treated by tyrosine kinase inhibitor (TKI). Previously, imatinib resistance in CML was treated with nilotinib as a second line. However, in Indonesia, where the options of TKIs are li... see more

Various tyrosine kinase inhibitor (TKI) drugs have been widely used as therapy for cancer that has EGFR mutations, or abnormal EGFR activation. However, patients who have a mutation in the gene that activates EGFR only benefit from EGFR-TKI therapy for le... see more

The efficiency of using the culture techniques of research for monitoring the patient’s response to the treatment by tyrosine kinase inhibitors of the first and second generation is shown. Thus, the functional activity of bone marrow cells in patients hav... see more

A functional activity of erythroid hematopoietic cells of patients with chronic myeloid leukemia, who were treated with tyrosine kinase inhibitor of the first and second generation was investigated. Samples of bone marrow of patients with resistance ... see more

Tyrosine kinase inhibitors are a class of chemotherapeutic drugs that target specific protein kinases. These tyrosine kinase inhibitors constitute a relatively new class of drugs which target for instance Bcr-Abl, Epidermal Growth Factor Receptor (EGFR) a... see more

Protein tyrosine kinases form an important target for a new class of anticancer drugs, the tyrosine kinase inhibitors (TKIs). Recently we demonstrated that sunitinib, an inhibitor of the membrane-associated vascular endothelial growth factor receptor (VEG... see more

Many potentially valuable drugs, including protein kinase inhibitors (PKI), risk being dropped from further development, without exploration of their clinical benefits, if early studies show these drugs to inhibit hERG channel and therefore, to have a pot... see more

1 of 601 pages  |  10  records  |  more records»